SMET12 combined with PD-1 monoclonal antibody toripalimab was reported to exhibit a synergistic anti-tumor effect in patient-derived xenograft (PDX) models, and results from two ongoing clinical trials also showed a preliminary anti-tumor efficacy and high safety (25, 26). Here, PDCD1 is linked to neoplasm.